The problematic HTA Review options paper should trigger a discussion of how agreements with the federal government have moved so far from their original intent of rewarding the industry's acceptance of pricing reforms to become platforms for policymakers to accelerate their own ambitions for change.
Agreements that started with limits have become vehicles for government-initiated change
March 1, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News
